APA (7th ed.) Citation

FA, H., B, M., S, D., SKL, C., B, E., J, M., . . . A, C. (2023). Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. European journal of cancer (Oxford, England : 1990), 184, 48. https://doi.org/10.1016/j.ejca.2023.02.002

Chicago Style (17th ed.) Citation

FA, Holmes, et al. "Overall Survival with Neratinib After Trastuzumab-based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." European Journal of Cancer (Oxford, England : 1990) 184 (2023): 48. https://doi.org/10.1016/j.ejca.2023.02.002.

MLA (9th ed.) Citation

FA, Holmes, et al. "Overall Survival with Neratinib After Trastuzumab-based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." European Journal of Cancer (Oxford, England : 1990), vol. 184, 2023, p. 48, https://doi.org/10.1016/j.ejca.2023.02.002.